Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Nov 7, 2023, after the close
10-Q filed Nov 7, 2023, 38 days after period end · 0001558370-23-017987
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $28.13M | $22.41M | $21.54M | $18.39M |
| Net Income | -$5.69M | -$19.04M | -$20.95M | -$14.17M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.33 |
| -$0.11 |
| -$0.12 |
| -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
